Biogen, Eisai and Alzheimer's disease

EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug
European Union's human medicines committee (CHMP) said on Friday it is not updating its opinion on Eisai and Biogen's Alzheimer's drug Leqembi, after it recommended its approval in November.
Biogen, Eisai confirm CHMP positive opinion for lecanemab
Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has
Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug
Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi.
EU regulator completes safety review of Eisai-Biogen's Alzheimer's drug without changes
The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's drug Leqembi without finding the need for any changes to the drug's status.
Biogen, Eisai announces CHMP of EMA reaffirmed positive opinion of lecanemab
Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA,
EU regulator reiterates positive recommendation for Alzheimer’s drug
The European Union’s medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen’s Alzheimer’s drug, Leqembi, after concluding a safety review.
FiercePharma3d
Eisai to part ways with 121 employees amid new US restructuring effort
Amid Eisai’s efforts to capitalize on a potential growth surge for its Alzheimer’s disease med Leqembi, the Japanese ...
BioSpace2d
Eisai Will Trim About 7% of US Workforce, Including New Jersey Employees
Eisai’s cuts will affect 121 employees across the Japanese company’s U.S. operations, including 57 people at its American ...
NJBIZ2d
More layoffs coming to NJ’s pharma sector
Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...
Eisai: Will Have No Problem Hitting Leqembi Forecasts
Eisai (ESALF) delivered another quarter with Leqembi growth, which is picking up strongly on a sequential basis. Read why I'm ...
Therapeutic Goods Administration decides not to register lecanemab in Australia
BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia has declined the approval of lecanemab (generic ...
BioArctic: Therapeutic Goods Administration decides not to register lecanemab in Australia
BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) of Australia ...
Contract Pharma2d
Eisai Licenses Tasurgratinib to SciClone in Greater China Region
Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions.
FiercePharma2d
Fierce Pharma Asia—Eisai's US restructuring; China investigates former NMPA official; Pfizer-Summit collab
Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by ...